<DOC>
	<DOCNO>NCT02056366</DOCNO>
	<brief_summary>The purpose study see safe effective give alpha lipoic acid people cardiac autonomic neuropathy ( CAN ) . Cardiac autonomic neuropathy ( CAN ) affect nerve control heart rate blood flow heart people diabetes . CAN may cause problem rhythm heartbeat decrease blood flow heart .</brief_summary>
	<brief_title>The Effect α-lipoic Acid Treatment Patient With Cardiac Autonomic Neuropathy</brief_title>
	<detailed_description>Study type : Interventional Study Design : Allocation : Randomized Control : treatment Endpoint Classification : Safety/Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment Primary Outcome Measures : Heart rate variability ( HRV ) Index Secondary Outcome Measures : Autonomic Nerve System ( ANS ) function 5 test , EuroQoL 5-Dimension Questionnaire ( EQ-5D )</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Inclusion Criteria : Established Cardiac Autonomic Neuropathy type 2 diabetes . age 20 year 80 year Capable give informed consent Exclusion Criteria : History significant disease nerve system ( Parkinson 's disease , epilepsy , multiple sclerosis ) , hepatic disease , hypothyroid , etc Other medical condition treatment likely affect autonomic nerve system HbA1C &gt; 11 % Not control hypertension ( SBP≥160mmHg , DBP≥100mmHg ) Diagnosed ketoacidosis within 4 week Unstable cardiac disease ( unstable angina myocardial infarction ) Pregnancy Involvement clinical trial last 4 week Known suspected sensitivity trial product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Cardiac Autonomic Neuropathy</keyword>
</DOC>